Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 6.
doi: 10.1007/s00277-025-06570-0. Online ahead of print.

Comparison of prognostication by IPSS-M, IPSS-R and AIPSS-MDS in the context of limited availability of molecular data in daily clinical practice

Felicitas Schulz  1 , Carolin Kellersmann  2 , Beate Betz  3 , Barbara Hildebrandt  3 , Annika Kasprzak  2 , Corinna Strupp  2 , Felicitas Thol  4 , Michael Heuser  4 , Christina Ganster  5 , Fabian Beier  6 , Katja Sockel  7 , Wolf-Karsten Hofmann  8 , Andrea Kuendgen  2 , Paul Jaeger  2 , Michael Pfeilstoecker  9 , Michael Lauseker  10 , Sascha Dietrich  2 , Nobert Gattermann  2 , Kathrin Nachtkamp  2 , Detlef Haase  5 , Ulrich Germing  2
Affiliations

Comparison of prognostication by IPSS-M, IPSS-R and AIPSS-MDS in the context of limited availability of molecular data in daily clinical practice

Felicitas Schulz et al. Ann Hematol. .

Abstract

The IPSS-M was developed to revolutionize the prediction of MDS patients' survival by incorporating molecular data. To compensate for lack of access to molecular analyses, the AIPSS-MDS, a supervised machine learning algorithm exclusively based on clinical and cytogenetic data, was developed by the Spanish MDS Group. We used data of the Düsseldorf MDS Registry and included 207 of more than 8500 registry patients whose IPSS-M-requested complete molecular data were known to compare and validate prognostication regarding OS and LFS of the IPSS-M, IPSS-R and AIPSS-MDS. All three tools reliably prognosticated median OS of patients even in a comparatively small patient cohort. The IPSS-M provided the most accurate prediction of median OS while the frequent lack of molecular data persists as an obstacle in daily clinical practice. Due to these circumstances, the IPSS-R remains the prognostication tool with the widest applicability. Based on our data, prognostication using the AIPSS-MDS is also feasible but less precise.

Keywords: IPSS; MDS; Myelodysplastic syndromes; Prognostication.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests. Conflict of interest disclosure: The authors declare no competing financial interests for the work described in this manuscript. Ethics and consent to participate: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Heinrich-Heine University in Duesseldorf. Informed consent was obtained from all subjects in the study.

References

    1. Cazzola M (2020) Myelodysplastic syndromes. N Engl J Med 383:1358–1374. https://doi.org/10.1056/NEJMra1904794 - DOI - PubMed
    1. Platzbecker U (2019) Treatment of MDS. Blood 133:1096–1107 - DOI - PubMed
    1. Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours. Myeloid and Histiocytic/Dendritic Neoplasms, Leukemia
    1. Greenberg P, Tuechler H, Schanz J et al (2012) Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood
    1. Bernard E, Tuechler H, Greenberg PL et al (2022) Molecular international prognostic scoring system for myelodysplastic syndromes. New Engl J Med NEJM Evid 1 (7)

LinkOut - more resources